136 results for «100»

Filter By

136 results

EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial

21 May 2025

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial

TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome

03 Sep 2025

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Author

Aaysha Cader
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome

Surgical left atrial appendage occlusion in VHD without AF: OPINION Trial

03 Sep 2025

Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Alessandro Sticchi

Author

Alessandro Sticchi
OPINION Trial: 1-year outcomes

ESC Practice Guidelines 2024: chronic coronary syndromes

30 Aug 2024

Julia Grapsa provides her take on the Chronic Coronary Syndromes (CCS) Guidelines which were presented by Felicita Andreotti and Christiaan Vrints at ESC Congress 2024 in London.

Julia Grapsa

Author

Julia Grapsa
ESC Guidelines: chronic coronary syndromes

EuroPCR 2025 – The place to share solutions

07 May 2025

The annual World-Leading Course in interventional cardiovascular medicine is the official meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI).  Thousands of participants will once again be gathering to share their knowledge, skills and experience on 20-23 May 2025, at the Palais des Congrès in...

3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

22 Mar 2022

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

Author

Ali Nazmi Calik
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

Amulet IDE: Amplatzer Amulet left atrial appendage occluder randomised controlled trial

31 Aug 2021

Luigi Biasco reports the best of Dj Lakkireddy (Overland Park, USA)'s presentation of the AMULET IDE trial at the Monday, August 30 Hot Line session of the ESC Congress 2021.

Luigi Biasco

Author

Luigi Biasco
ESC Congress 2021 - Amulet IDE: Amplatzer Amulet left atrial appendage occluder randomised controlled trial

The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030

29 Aug 2021

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Vijay Kunadian

Author

Vijay Kunadian
ESC Congress 2021 - Global burden of cardiovascular disease in women; 20/20 vision for 2030: report of The Lancet commission

World's first angioplasty patient is still going strong

16 May 2017

 
Forty years ago, Andreas Grüntzig performed the world’s first coronary angioplasty (PCI)—fundamentally changing the management of coronary artery disease. Bernhard Meier, who worked with A. Grüntzig and actually identified the patient for the procedure, talks to The Daily Wire about this first procedure and about his...

Andreas Grüntzig in 1975

Pursue Classics·Originality - Gusta® Balloon Seminar Salon:Beijing Station

22 Apr 2022

What’s new in the 2020 ESC Clinical Practice Guideline on the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS)?

29 Aug 2020

Majority of ischemic heart disease patients present with NSTEACS . Management of NSTEACS starts with correct diagnosis, appropriate timely initiation of the right pharmacotherapy, provision of coronary angiography/intervention procedures and secondary preventative care. 5 years on from the last ESC NSTEACS guidelines, what does the new...

Vijay Kunadian

Author

Vijay Kunadian
ESC NSTEACS guidelines 2020

The impact of COVID-19 pandemic on interventional cardiologists in training

23 Oct 2020

In collaboration with EuroIntervention Journal

The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...

The impact of COVID-19 pandemic on interventional cardiologists in training

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!

17 Oct 2020

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Author

Hector Garcia
Live from TCT Connect 2020: PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB

COVID-19 vaccines: Burning questions from the community and real-world applicability

13 Jan 2021

View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.

COVID-19 vaccines: Burning questions from the community and real-world applicability

Comparison of a precision care strategy with usual testing to guide management of stable patients with suspected CAD: the PRECISE randomized trial

09 Nov 2022

Alex Sticchi provides his take on PRECISE, which was presented during AHA 2022 in Chicago.

Alessandro Sticchi

Author

Alessandro Sticchi
Comparison of a precision care strategy with usual testing to guide management of stable patients with suspected coronary artery disease: the PRECISE randomized trial

Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial

09 Apr 2024

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)

Daniele Giacoppo

Author

Daniele Giacoppo
Marco Spagnolo

Author

Marco Spagnolo
IVUS-guided vs angiography-guided PCI in acute coronary syndromes
Didn’t find what you were looking for?